Major Pharmaceutical Deal: AstraZeneca Expands Control Over Roxadustat in China
A significant development in the pharmaceutical industry has emerged as AstraZeneca establishes full control over the commercialization of roxadustat in China through a strategic acquisition of its partner FibroGen‘s China operations for $160 million. This transaction, announced on Thursday, ensures that AstraZeneca will oversee all aspects of this anemia treatment in a market where it has rapidly gained popularity. The funds from this agreement will provide FibroGen with the necessary resources to strengthen its financial standing while shifting its focus towards the clinical development of a new cancer drug that has emerged as its primary asset.
Roxadustat: A Revolutionary Treatment for Anemia Linked to Chronic Kidney Disease
Roxadustat, a novel drug classified as a HIF-PH inhibitor, has been pivotal in increasing the production of erythropoietin, a hormone essential for the formation of red blood cells. This mechanism effectively combats anemia associated with chronic kidney disease (CKD). Since its approval in 2019, China has recognized Roxadustat as a leading treatment option in this therapeutic area. Additionally, the drug is currently undergoing regulatory scrutiny in China as a potential solution for chemotherapy-induced anemia, which could further augment its market presence.
AstraZeneca and FibroGen: A Partnership with a Shared Vision for Roxadustat
The collaboration between AstraZeneca and FibroGen dates back to 2013, marking the inception of two crucial agreements. One agreement encompassed the development and commercialization of Roxadustat in the U.S. and other regions, excluding Europe and Japan, where Astellas Pharma holds the rights. The second agreement was specific to the Chinese market, ensuring an equal profit-sharing arrangement. This partnership has played a significant role in the drug’s success and market penetration.
Recent Developments: Roxadustat Faces Regulatory Challenges in the U.S.
In 2021, Roxadustat gained approval in Europe but faced setbacks with the FDA, which mandated another clinical trial before granting approval in the U.S. Subsequently, AstraZeneca and FibroGen dissolved their collaboration agreement for Roxadustat in the U.S. and other regions, retaining only the partnership in China and areas licensed to Astellas Pharma. The recent deal solidifies the end of this collaboration, with financial terms revealing an $85 million cash flow for the enterprise value of the China business along with approximately $75 million in net cash held by the business and its subsidiaries. The agreement is projected to finalize by mid-year.
Future Plans: FibroGen’s Strategy for Roxadustat and New Developments
Despite relinquishing control in China, FibroGen remains committed to advancing Roxadustat’s development in the U.S. The company still retains rights in this market, even after the drug’s disappointing Phase 3 results for treating anemia related to lower-risk myelodysplastic syndrome, a type of blood cancer. FibroGen believes there is a significant unmet medical need in this area and plans to consult with the FDA in the second quarter of this year to discuss possible pathways for Roxadustat’s development.
Financial Position and Future Prospects for FibroGen
As of the end of 2024, FibroGen reported a cash position of approximately $121.1 million. The proceeds from the AstraZeneca agreement will be allocated to debt repayment, while the company will continue its clinical development of FG-3246, an antibody-drug conjugate acquired from Fortis Therapeutics in 2023. A Phase 2 trial for this promising drug candidate in patients with metastatic castration-resistant prostate cancer is anticipated to commence in the second quarter of this year. With these developments, FibroGen expects its cash runway to extend into 2027, positioning itself favorably for future growth.
Strategic Decision: FibroGen’s CEO Discusses the Sale of China Operations
In a prepared statement, FibroGen CEO Thane Wettig emphasized that after a thorough evaluation of alternatives, the decision to sell its China operations and repay the term loan was made in the best interest of FibroGen’s stakeholders. This strategic move is anticipated to enhance the company’s operational focus and financial health, allowing it to concentrate on its U.S. assets.
Analyst Insights: The Transaction as a Positive Outcome for FibroGen
According to analyst Andy Hsieh from William Blair, the recent transaction is seen as a favorable outcome for FibroGen’s China business. In a research note, Hsieh highlighted that the deal facilitates the repatriation of cash generated in China back to the U.S., effectively extending FibroGen’s cash runway. This financial boost will support clinical trials for both FG-3246 and potentially Roxadustat, should an agreement be reached with the FDA. For investors, the deal clarifies the investment narrative, now streamlined to focus on two core assets with U.S. rights.
For more of the latest in litigation, regulation, deals, and financial services trends, sign up for Finance Docket, a partnership between Breaking Media publications Above the Law and Dealbreaker.
